31. Consolidated companies as of 31 December 2020

Notes to the consolidated financial statements
CSR report

Name of the subsidiary

Country

% voting right
Galapagos NV
(directly or indirectly through subsidiaries)

Change in % voting
right previous period
(2020 vs 2019)

Biofocus DPI AG (liquidated)

Switzerland

0%

(100%)

Galapagos Biopharma Belgium BV

Belgium

100%

-

Galapagos Biopharma Netherlands B.V.

The Netherlands

100%

-

Galapagos Biopharma Spain S.L.U

Spain

100%

-

Galapagos Biopharma Italy S.r.l.

Italy

100%

-

Galapagos Biopharma Germany GmbH

Germany

100%

-

Galapagos Biotech Ltd.

United Kingdom

100%

-

Galapagos BV

The Netherlands

100%

-

Galapagos GmbH

Switzerland

100%

-

Galapagos, Inc.

United States

100%

-

Galapagos NV

Belgium

Parent company

-

Galapagos Real Estate Belgium BV

Belgium

100%

-

Galapagos Real Estate Netherlands B.V.

The Netherlands

100%

-

Galapagos SASU

France

100%

-

Fidelta d.o.o.

Croatia

100%

-

Xenometrix, Inc. in liquidation

United States

100%

-

In the course of 2020 we merged Galapagos Real Estate 2 BV with Galapagos Real Estate 1 BV, with the latter being the surviving entity whose company name changed into Galapagos Real Estate Belgium BV. Our dormant Swiss subsidiary BioFocus DPI AG was deconsolidated in 2020 and the final actions for its liquidation were completed in 2020. In 2021 solely its deregistration from the Swiss commercial register still needs to occur.

On 23 November 2020 we signed a share purchase agreement for the sale of our subsidiary Fidelta d.o.o. (Zagreb, Croatia). As we expect that the net assets associated with Fidelta d.o.o. will be recovered principally through a sale transaction rather than through continuing use, we have classified these assets and the associated liabilities as held for sale in our financial statements for the year ended 31 December 2020. On 4 January 2021 we closed the sale of our fee-for-service business Fidelta. Selvita S.A. acquired 100% of the outstanding shares in Fidelta.

There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.